Chronic Hepatitis B and Hepatitis D Virus Infection

被引:0
作者
Rusignuolo, Giuseppe [1 ,2 ]
Thimme, Robert [1 ]
Neumann-Haefelin, Christoph [1 ,2 ]
机构
[1] Uni Klin Freiburg, Klin Innere Med 2, Freiburg, Germany
[2] Gerok Leberzentrum, Freiburg, Germany
关键词
Hepatitis-B-Virus; Hepatitis-D-Virus; Therapie; antiviral; Entecavir; Tenofovir; Bulevirtid; hepatitis B virus; hepatitis D virus; therapy; entecavir; tenofovir; bulevirtide; BULEVIRTIDE; EFFICACY; PHASE-3; SAFETY; TRIAL;
D O I
10.1055/a-2057-1840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Eine unbehandelte chronische Hepatitis-B-Virus-Infektion kann bis zur Leberzirrhose und zum hepatozellul & auml;ren Karzinom fortschreiten, was durch eine rechtzeitige Diagnose und eine antivirale Therapie verhindert werden kann. Eine Heilung ist bisher aber in der Regel nicht m & ouml;glich. Eine Koinfektion mit dem Hepatitis-D-Virus erh & ouml;ht das Risiko einer Leberzirrhose. Auch f & uuml;r die Hepatitis D steht inzwischen eine effektive Therapie zur Verf & uuml;gung. About 0,5% of the population in Germany has a chronic hepatitis B virus (HBV) infection. Untreated, chronic HBV infection can progress to liver cirrhosis and hepatocellular carcinoma (HCC). If diagnosed early, antiviral therapy can effectively prevent liver disease progression, but a cure is currently hardly achievable. About 5% of those chronically infected with HBV are also co-infected with the hepatitis D virus (HDV). HBV/HDV co-infection leads to liver cirrhosis in approximately 50% of patients within 5-10 years. Since 2020, the cell entry inhibitor bulevirtide is available as a specific therapy for HBV/HDV co-infection.
引用
收藏
页码:948 / 954
页数:7
相关论文
共 24 条
  • [11] EASL Clinical Practice Guidelines on hepatitis delta virus br
    European Assoc Study Liver
    [J]. JOURNAL OF HEPATOLOGY, 2023, 79 (02) : 433 - 460
  • [12] Hirode G, 2022, GASTROENTEROLOGY, V162, P757, DOI 10.1053/j.gastro.2021.11.002
  • [13] What will it take to cure hepatitis B?
    Jeng, Wen-Juei
    Lok, Anna S. F.
    [J]. HEPATOLOGY COMMUNICATIONS, 2023, 7 (04)
  • [14] HCC surveillance of patients with chronic viral hepatitis
    Neumann-Haefelin, Christoph
    [J]. GASTROENTEROLOGE, 2021, 16 (06): : 450 - 454
  • [15] Sandmann L., 2023, der Deutschen Gesellschaft fur Gastroenterologie, Verdauungsund Stoffwechselkrankheiten (DGVS) (AWMF-Registernummer 021-11)
  • [16] Interferon-based treatment of chronic hepatitis D
    Sandmann, Lisa
    Wedemeyer, Heiner
    [J]. LIVER INTERNATIONAL, 2023, 43 : 69 - 79
  • [17] Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
    Sonneveld, Milan J.
    Chiu, Shao-Ming
    Park, Jun Yong
    Brakenhoff, Sylvia M.
    Kaewdech, Apichat
    Seto, Wai-Kay
    Tanaka, Yasuhito
    Carey, Ivana
    Papatheodoridi, Margarita
    van Bommel, Florian
    Berg, Thomas
    Zoulim, Fabien
    Ahn, Sang Hoon
    Dalekos, George N.
    Erler, Nicole S.
    Zu Siederdissen, Christoph Honer
    Wedemeyer, Heiner
    Cornberg, Markus
    Yuen, Man-Fung
    Agarwal, Kosh
    Boonstra, Andre
    Buti, Maria
    Piratvisuth, Teerha
    Papatheodoridis, George
    Chen, Chien-Hung
    Maasoumy, Benjamin
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (05) : 1042 - 1050
  • [18] The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis
    Stockdale, Alexander J.
    Kreuels, Benno
    Henrion, Marc Y. R.
    Giorgi, Emanuele
    Kyomuhangi, Irene
    de Martel, Catherine
    Hutin, Yvan
    Geretti, Anna Maria
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 (03) : 523 - 532
  • [19] Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity
    Suarez, Armando A. Roca A.
    Batbold, Enkhtuul
    Bartosch, Birke
    Dashdorj, Naranjargal
    Testoni, Barbara
    Zoulim, Fabien
    [J]. LIVER INTERNATIONAL, 2023, 43 : 87 - 95
  • [20] Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus
    Tarik, Asselah
    [J]. JOURNAL OF VIRAL HEPATITIS, 2023, 30 : 33 - 38